首页> 美国卫生研究院文献>ACS Omega >Synthesis Biological Evaluation and Molecular Docking of Novel Azolylhydrazonothiazoles as Potential Anticancer Agents
【2h】

Synthesis Biological Evaluation and Molecular Docking of Novel Azolylhydrazonothiazoles as Potential Anticancer Agents

机译:新型偶氮肼噻唑作为潜在抗癌剂的合成、生物学评价和分子对接

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A novel set of thiazolylhydrazonothiazoles bearing an indole moiety were synthesized by subjection reactions of carbothioamide derivative and hydrazonoyl chlorides (or α-haloketones). The cytotoxicity of the synthesized compounds was evaluated against the colon carcinoma cell line (HCT-116), liver carcinoma cell line (HepG2), and breast carcinoma cell line (MDA-MB-231), and demonstrated encouraging activity. Furthermore, when representative products were assessed for toxicity against normal cells, minimal toxic effects were observed, indicating their potential safety for use in pharmacological studies. The mechanism of action of the tested products, as inhibitors of the epidermal growth factor receptor tyrosine kinase domain (EGFR TK) protein, was suggested through docking studies that assessed their binding scores and modes, in comparison to a reference standard (W19), thus endorsing their anticancer activity.
机译:通过羚酰基酰胺衍生物和肼唑酰氯(或α-卤酮)的受试反应合成了一组带有吲哚部分的新型噻唑酰肼噻唑。针对结肠癌细胞系 (HCT-116) 、肝癌细胞系 (HepG2) 和乳腺癌细胞系 (MDA-MB-231) 评估合成化合物的细胞毒性,并显示出令人鼓舞的活性。此外,当评估代表性产品对正常细胞的毒性时,观察到最小的毒性作用,表明它们在药理学研究中使用具有潜在安全性。通过对接研究提出受试产品作为表皮生长因子受体酪氨酸激酶结构域 (EGFR TK) 蛋白抑制剂的作用机制,该研究评估了它们的结合评分和模式,与参考标准 (W19) 进行比较,从而认可了它们的抗癌活性。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号